The Drug Regulatory Authority of Pakistan finished a three-day workshop alongside provincial and state drug control administrations to improve market surveillance, quality assurance, and regulatory coordination for medical products nationwide.
Regulatory officials from all over Pakistan gathered for the event, which centered on risk-based sampling, market surveillance, the Market Control Dashboard, and Electronic Quality Management Systems to build technical capacity and share experiences.
The World Health Organization provided technical support for the program, which seeks to unify medical product regulation and improve cooperation between federal, provincial, and state regulatory bodies.
Attendees talked about methods to better monitor markets, improve risk-based sampling, and use digital tools for regulatory choices to oversee medical goods more effectively.
The sessions also stressed the necessity of working together to spot and stop the distribution of fake and substandard medical items that threaten public health and patient safety.
Delegates underscored the requirement for a solid national regulatory structure, renewing their dedication to boosting interprovincial teamwork, upgrading market control tools, and making regulatory work more efficient.
Better market surveillance instruments and electronic quality management systems should help streamline regulatory tasks, improve data sharing between agencies, and allow fast reactions to safety issues.
This program belongs to wider plans to build a more responsive and capable National Regulatory System that guarantees medical items in Pakistan match required levels of quality, safety, and effectiveness.
Officials from DRAP and provincial and state agencies renewed their pledge to cooperate on safeguarding patients, raising regulatory standards, and encouraging availability of safe and quality-assured medical products across the nation.
